Filing Details
- Accession Number:
- 0001209191-22-003195
- Form Type:
- 4
- Zero Holdings:
- No
- Publication Time:
- 2022-01-13 16:36:02
- Reporting Period:
- 2022-01-11
- Accepted Time:
- 2022-01-13 16:36:02
- SEC Url:
- Form 4 Filing
Issuer
| Cik | Name | Symbol | Sector (SIC) | IRS No |
|---|---|---|---|---|
| 1868734 | Cincor Pharma Inc. | CINC | () | I0 |
Insiders
| Cik | Name | Reported Address | Insider Title | Director | Officer | Large Shareholder | Other |
|---|---|---|---|---|---|---|---|
| 1574139 | Sas Partners Sofinnova | 7-11 Boulevard Haussmann Paris I0 75009 | No | No | Yes | No | |
| 1849915 | Ix Capital Sofinnova | 7-11 Boulevard Haussmann Paris I0 75009 | No | No | Yes | No |
Reported Non-Derivative Transactions
| Sec. Name | Acquisiton - Disposition | Date | Amount | Price | Remaning Holdings | Equity Swap Involved | Form Type | Code | Nature of Ownership | Explanation |
|---|---|---|---|---|---|---|---|---|---|---|
| Common Stock | Acquisiton | 2022-01-11 | 3,867,646 | $0.00 | 3,867,646 | No | 4 | C | Indirect | By Sofinnova Capital IX |
| Common Stock | Acquisiton | 2022-01-11 | 220,000 | $16.00 | 4,087,646 | No | 4 | P | Indirect | By Sofinnova Capital IX |
| Equity Swap Involved | Form Type | Code | Nature of Ownership | Explanation |
|---|---|---|---|---|
| No | 4 | C | Indirect | By Sofinnova Capital IX |
| No | 4 | P | Indirect | By Sofinnova Capital IX |
Reported Derivative Transactions
| Sec. Name | Sec. Type | Acquisiton - Disposition | Date | Amount | Price | Amount - 2 | Price - 2 |
|---|---|---|---|---|---|---|---|
| Common Stock | Series A Preferred Stock | Disposition | 2022-01-11 | 9,999,999 | $0.00 | 2,941,176 | $0.00 |
| Common Stock | Series B Preferred Stock | Disposition | 2022-01-11 | 3,150,000 | $0.00 | 926,470 | $0.00 |
| Remaning Holdings | Exercise Date | Expiration Date | Equity Swap Involved | Transaction Form Type | Transaction Code | Nature of Ownership |
|---|---|---|---|---|---|---|
| 0 | No | 4 | C | Indirect | ||
| 0 | No | 4 | C | Indirect |
Footnotes
- Each share of Series A Preferred Stock and Series B Preferred Stock automatically converted into shares of Common Stock immediately prior to the closing of the Issuer's initial public offering (the "IPO") for no additional consideration, on a 3.4:1 basis, and had no expiration date.
- The shares are directly held by Sofinnova Capital IX ("SC IX"). Sofinnova Partners SAS ("Sofinnova Partners") is the management company of SC IX and may bedeemed to share voting and investment power over the shares held by SC IX. Sofinnova Partners disclaims beneficial ownership of these shares except to theextent of its pecuniary interest therein.
Billionaire Hedge Funds
